title: Evaluation of WO2012003387, Gilead's ASK1 inhibitors.
abstract: A small number of novel N-(triazolylthiazol-2-yl) and N-(triazolylthienyl) benzamide and picolinamide derivatives are claimed. The compounds are ASK1 kinase inhibitors among which some have nanomolar potency and are potentially useful in the treatment of a diverse range of conditions. The claimed compounds define a pharmacophore, distinct from that described in the limited number of patent filings claiming ASK1 inhibitors.
authors.affiliation: Norman Consulting, Burnham, Bucks, UK. peter.norman2@btinternet.com
authors.forename: Peter
authors.initials: P
authors.lastname: Norman
mesh_terms: D000818:Animals; D015195:Drug Design; D006801:Humans; D048848:MAP Kinase Kinase Kinase 5 / Q000037:antagonists & inhibitors* / Q000378:metabolism; D015394:Molecular Structure; D010330:Patents as Topic; D047428:Protein Kinase Inhibitors / Q000737:chemistry / Q000494:pharmacology*; D013329:Structure-Activity Relationship
chemical_list: D047428:Protein Kinase Inhibitors; D048848:MAP Kinase Kinase Kinase 5